As of January 22, 2025, Inhibrx (INBX) has a market cap of $0.20 billion USD. According to our data, Inhibrx is ranked No.7122 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.20 B |
-11.69%
|
Dec 31, 2024 | $0.22 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
Market Cap | = | INBX Stock Price | * | INBX Shares Outstanding |
= | $13.60 | * | 14.48 M | |
= | $0.20 B |